By Professor Peter Ian Croucher

Journal articles

Esapa C; Head R; Jeyabalan J; Evans HR; Hough TA; Cheeseman M; Mcnally EG; Carr A; Thomas GP; Brown M; Croucher PI; Brown S; Cox R, 2012, 'A mouse with an N-Ethyl-N-Nitrosourea (ENU) induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis', PLoS One, 7, pp. e43205, http://dx.doi.org/10.1371/journal.pone.0043205

Baud''huin M; Solban N; Cornwall-Brady M; Sako D; Kawamoto Y; Liharska K; Lath D; Bouxsein ML; Underwood KW; Ucran JA; Kumar RSP; Pobre EG; Grinberg AV; Seehra JS; Canalis EM; Pearsall RS; Croucher PI, 2012, 'A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength', Proceedings of the National Academy of Sciences of the United States of America, 109, pp. 12207 - 12212, http://dx.doi.org/10.1073/pnas.1204929109

Bassett JHD; Logan JG; Boyde A; Cheung MS; Evans HR; Croucher P; Sun XY; Xu S; Murata Y; Williams GR, 2012, 'Mice lacking the calcineurin inhibitor Rcan2 have an isolated defect of osteoblast function', Endocrinology, 153, pp. 3537 - 3548, http://dx.doi.org/10.1210/en.2011-1814

Bassett JHD; Gogakos A; White J; Evans HR; Jacques RM; Spek PVD; Ramirez-solis R; Ryder EJ; Sunter D; Boyde A; Campbell MJ; Croucher PI; Williams GR, 2012, 'Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength', PLoS Genetics, 8, pp. e1002858, http://dx.doi.org/10.1371/journal.pgen.1002858

Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI, 2012, 'Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma', PLoS One, 7, pp. e41127, http://dx.doi.org/10.1371/journal.pone.0041127

Vitovski S; Chantry AD; Lawson MA; Croucher PI, 2012, 'Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo', PLoS One, 7, pp. e35830, http://dx.doi.org/10.1371/journal.pone.0035830

Clézardin P; Benzaïd I; Croucher PI, 2011, 'Bisphosphonates in preclinical bone oncology', Bone, 49, pp. 66 - 70, http://dx.doi.org/10.1016/j.bone.2010.11.017

Gambardella A; Nagaraju CK; O'Shea PJ; Mohanty ST; Kottam L; Pilling J; Sullivan M; Djerbi M; Koopmann W; Croucher PI; Bellantuono I, 2011, 'Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage', Journal of Bone and Mineral Research, 26, pp. 811 - 821, http://dx.doi.org/10.1002/jbmr.266

Felber K; Croucher P; Roehl HH, 2011, 'Hedgehog signalling is required for perichondral osteoblast differentiation in zebrafish', Mechanisms of Development, 128, pp. 141 - 152, http://dx.doi.org/10.1016/j.mod.2010.11.006

Fowler JA; Edwards CM; Croucher PI, 2011, 'Tumor-host cell interactions in the bone disease of myeloma', Bone, 48, pp. 121 - 128, http://dx.doi.org/10.1016/j.bone.2010.06.029

Kassen D; Rabin N; Lath D; Croucher P; Yong K, 2011, 'Deregulation of the bone marrow stromal compartment occurs early in multiple myeloma and precedes osteolytic bone disease', Bone, 48, pp. S253 - S254, http://dx.doi.org/10.1016/j.bone.2011.03.619

Buckle* C; Andersen T; Delaisse J-M; Vanderkerken K; Croucher PI, 2011, 'Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease', Bone, 48, pp. S19 - S19, http://dx.doi.org/10.1016/j.bone.2010.10.049

Kassen* D; Rabin N; Lath D; Croucher PI; Yong K, 2011, 'Mechanisms of osteoblast supression in multiple myeolma', Bone, 48, pp. S37 - S37, http://dx.doi.org/10.1016/j.bone.2010.10.103

Williams* AJ; Lawson MA; Alamer O; Hough J; Bos T; Vanderkerken K; Croucher PI, 2011, 'Multiphoton imaging of individual myeloma cells in calvariae: Association of myeloma development with sites of bone turnover', Bone, 48, pp. S14 - S14, http://dx.doi.org/10.1016/j.bone.2010.10.037

Vitovski* S; Chantry AD; Lawson MA; Croucher PI, 2011, 'Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo', Bone, 48, pp. S15 - S15, http://dx.doi.org/10.1016/j.bone.2010.10.040

Lawson MA; Ashcroft J; Croucher PI, 2010, 'Bisphosphonate therapy in the treatment of multiple myeloma', Current Pharmaceutical Design, 16, pp. 3028 - 3036, http://dx.doi.org/10.2174/138161210793563608

Coleman RE; Lipton A; Roodman GD; Guise TA; Boyce BF; Brufsky AM; Clézardin P; Croucher PI; Gralow JR; Hadji P; Holen I; Mundy GR; Smith MR; Suva LJ, 2010, 'Metastasis and bone loss: Advancing treatment and prevention', Cancer Treatment Reviews, 36, pp. 615 - 620, http://dx.doi.org/10.1016/j.ctrv.2010.04.003

Kassen D; Rabin N; Lath D; Croucher P; Yong K, 2010, 'The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo', Blood, 116, pp. 4052 - 4052, http://dx.doi.org/10.1182/blood.v116.21.4052.4052

Mohanty ST; Kottam L; Gambardella A; Nicklin MJ; Coulton L; Hughes D; Wilson AG; Croucher PI; Bellantuono I, 2010, 'Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis', Arthritis Research and Therapy, 12, http://dx.doi.org/10.1186/ar3098

Grčević D; Kušec R; Kovačić N; Lukić A; Lukić IK; Ivčević S; Nemet D; Seiwerth RS; Ostojić SK; Croucher PI; Marušić A, 2010, 'Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes', Leukemia Research, 34, pp. 742 - 751, http://dx.doi.org/10.1016/j.leukres.2009.10.016

Bassett JHD; Boyde A; Howell PGT; Bassett RH; Galliford TM; Archanco M; Evans H; Lawson MA; Croucher P; St. Germain DL; Galton VA; Williams GR, 2010, 'Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts', Proceedings of the National Academy of Sciences of the United States of America, 107, pp. 7604 - 7609, http://dx.doi.org/10.1073/pnas.0911346107

Kovacic N; Grcevic D; Katavic V; Lukic IK; Grubisic V; Mihovilovic K; Cvija H; Croucher PI; Marusic A, 2010, 'Fas receptor is required for estrogen deficiency-induced bone loss in mice', Laboratory Investigation, 90, pp. 402 - 413, http://dx.doi.org/10.1038/labinvest.2009.144

Li N; Kelsh RN; Croucher P; Roehl HH, 2010, 'Regulation of neural crest cell fate by the retinoic acid and Pparg signalling pathways', Development, 137, pp. 389 - 394, http://dx.doi.org/10.1242/dev.044164

Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'Huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P, 2010, 'Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo', Journal of Bone and Mineral Research, 25, pp. 2633 - 2646, http://dx.doi.org/10.1002/jbmr.142

Buckle CH; Neville-Webbe HL; Croucher PI; Lawson MA, 2010, 'Targeting RANK/RANKL in the treatment of solid tumours and myeloma', Current Pharmaceutical Design, 16, pp. 1272 - 1283, http://dx.doi.org/10.2174/138161210791034021

Feng R; Huang X; Coulton L; Raeve HD; DiLiberto M; Ely S; Xiao G; Luo M; Menu E; Croucher P; Roodman GD; Vanderkerken K; Chen-Kiang S; Lentzsch S, 2009, 'Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.', Blood, 114, pp. 298 - 298, http://dx.doi.org/10.1182/blood.v114.22.298.298

Terpos E; Sezer O; Croucher PI; García-Sanz R; Boccadoro M; San Miguel J; Ashcroft J; Bladé J; Cavo M; Delforge M; Dimopoulos MA; Facon T; Macro M; Waage A; Sonneveld P, 2009, 'The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network', Annals of Oncology, 20, pp. 1303 - 1317, http://dx.doi.org/10.1093/annonc/mdn796

Hald A; Hansen RR; Thomsen MW; Ding M; Croucher PI; Gallagher O; Ebetino FH; Kassem M; Heegaard AM, 2009, 'Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790', International Journal of Cancer, 125, pp. 1177 - 1185, http://dx.doi.org/10.1002/ijc.24436

Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; Broek IV; De Raeve H; Coulton L; Van Camp B; Croucher P; Vanderkerken K, 2009, 'Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma', Cancer Research, 69, pp. 5307 - 5311, http://dx.doi.org/10.1158/0008-5472.CAN-08-4472

Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI, 2009, 'Inhibiting dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma', Journal of Bone and Mineral Research, 24, pp. 425 - 436, http://dx.doi.org/10.1359/jbmr.081104

Li N; Felber K; Elks P; Croucher P; Roehl HH, 2009, 'Tracking gene expression during zebrafish osteoblast differentiation', Developmental Dynamics, 238, pp. 459 - 466, http://dx.doi.org/10.1002/dvdy.21838

Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K, 2009, 'The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models', Leukemia, 23, pp. 1894 - 1903, http://dx.doi.org/10.1038/leu.2009.121

Felber K; Elks P; Croucher P; Roehl H, 2009, '13-P049 FGF signalling is regulating bone development in zebrafish', Mechanisms of Development, 126, pp. S209 - S209, http://dx.doi.org/10.1016/j.mod.2009.06.522

Deleu SI; Arts J; Lemaire M; Menu E; Van Valckenborgh E; De Raeve H; Croucher P; Van Camp B; Vanderkerken K, 2009, 'B144 The Effect of JNJ-26481585 in Murine Myeloma Models', Clinical Lymphoma and Myeloma, 9, pp. S104 - S104, http://dx.doi.org/10.1016/s1557-9190(11)70664-3

Chantry A; Coulton L; Gallagher O; Evans H; Seehra J; Pearsall S; De Raeve H; Vanderkerken K; Croucher P, 2009, 'Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma', Bone, 44, pp. S55 - S55, http://dx.doi.org/10.1016/j.bone.2009.01.465

Brown SDM; Esapa CT; Barbaric I; Hough T; Brown M; Croucher P; Head R; Chan C; Crane E; Cox R; Cheeseman M; Thakker RV, 2009, 'Genetic models of bone disease using ENU mutagenesis', Bone, 44, pp. S19 - S19, http://dx.doi.org/10.1016/j.bone.2009.01.041

Abdul N; Stoop W; Koopman W; Djerbi M; Chantry AD; Evans H; Vanderkerken K; Croucher PI, 2009, 'Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease', Bone, 44, pp. S53 - S54, http://dx.doi.org/10.1016/j.bone.2009.01.462

Lawson MA; Williams AJ; Bos T; Vanderkerken K; Croucher PI, 2009, 'Localising individual myeloma cells to the myeloma ‘niche’ in bone using multiphoton microscopy', Bone, 44, pp. S164 - S164, http://dx.doi.org/10.1016/j.bone.2009.01.384

Buckle CH; De Leenheer E; Lawson MA; Hough JM; Yong KL; Rabin N; Vanderkerken K; Croucher PI, 2009, 'Soluble RANK ligand produced by myeloma cells contributes to generalised bone loss in multiple myeloma', Bone, 44, pp. S162 - S162, http://dx.doi.org/10.1016/j.bone.2009.01.458

Li N; Felber K; Elks P; Croucher P; Roehl HH, 2009, 'Tracking gene expression during zebrafish osteoblast differentiation', Developmental Dynamics, 238, http://dx.doi.org/10.1002/dvdy.21904

Lawson MA; Coulton L; Ebetino FH; Vanderkerken K; Croucher PI, 2008, 'Geranylgeranyl transferase type II inhibition prevents myeloma bone disease', Biochemical and Biophysical Research Communications, 377, pp. 453 - 457, http://dx.doi.org/10.1016/j.bbrc.2008.09.157

Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA, 2008, 'Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (Leukemia (2008) vol. 22 (2247-2256) 10.1038/ leu.2008.2256)', Leukemia, 22, pp. 2292, http://dx.doi.org/10.1038/leu.2008.288

Lawrie A; Waterman E; Southwood M; Evans D; Suntharalingam J; Francis S; Crossman D; Croucher P; Morrell N; Newman C, 2008, 'Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension', American Journal of Pathology, 172, pp. 256 - 264, http://dx.doi.org/10.2353/ajpath.2008.070395

Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA, 2008, 'The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis', Leukemia, 22, pp. 2247 - 2256, http://dx.doi.org/10.1038/leu.2008.235

Heath D; Chantry A; Buckle C; Coulton L; Shaughnessy J; Evans H; Stover D; Vanderkerken K; Croucher P, 2008, 'OC7. Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma', Cancer Treatment Reviews, 34, pp. 52 - 52, http://dx.doi.org/10.1016/j.ctrv.2008.03.033

Ottewell P; Croucher P; Holen I, 2008, 'P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions', Cancer Treatment Reviews, 34, pp. 12 - 12, http://dx.doi.org/10.1016/j.ctrv.2008.03.042

Chantry A; Heath D; Coulton L; Evans H; Abdul N; Seehra J; Vanderkerken K; Croucher P, 2008, 'P3. A soluble activin type II receptor prevents the development of myeloma bone disease', Cancer Treatment Reviews, 34, pp. 13 - 14, http://dx.doi.org/10.1016/j.ctrv.2008.03.044

Xu J; Leenheer ED; Piasecki J; De Vries A-RV; Vanderkerken K; Croucher P, 2007, 'In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.', Blood, 110, pp. 1518 - 1518, http://dx.doi.org/10.1182/blood.v110.11.1518.1518

Vitovski S; Phillips JS; Sayers J; Croucher PI, 2007, 'Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand: Evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways', Journal of Biological Chemistry, 282, pp. 31601 - 31609, http://dx.doi.org/10.1074/jbc.M706078200

Menu E; Jernberg-Wiklund H; De Raeve H; De Leenheer E; Coulton L; Gallagher O; Van Valckenborgh E; Larsson O; Axelson M; Nilsson K; Van Camp B; Croucher P; Vanderkerken K, 2007, 'Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival', International Journal of Cancer, 121, pp. 1857 - 1861, http://dx.doi.org/10.1002/ijc.22845

Back to profile page